Changes and clinical significance of natural killer-like B cells, natural killer cells, and B cells in peripheral blood of patients with hepatitis B virus infection

Xiaofei YANG; Huanjun SHEN; Gaobo HUANG; Jianqi LIAN; Ye ZHANG

doi:10.3969/j.issn.1001-5256.2022.07.008

Volume 38 Issue 7

Jul. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(7): 1489-1494

PDF( 2862 KB)

Changes and clinical significance of natural killer-like B cells, natural killer cells, and B cells in peripheral blood of patients with hepatitis B virus infection

DOI: 10.3969/j.issn.1001-5256.2022.07.008

1.
Department of Infectious Diseases, The Second Affiliated Hospital of Air Force Medical University & Tangdu Hospital of Fourth Military Medical University, Xi'an 710038, China
2.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

Research funding:

National Natural Science Foundation of China (31370856);

National Natural Science Foundation of China (81671555)

More Information

Corresponding author: ZHANG Ye, zhangyefmmu@hotmail.com(ORCID: 0000-0002-2573-5471)
Received Date: 2021-11-24
Accepted Date: 2022-02-09
Published Date: 2022-07-20

Abstract

Abstract

Objective To investigate the changes of natural killer-like B (NKB) cells, natural killer (NK) cells, and B cells and their correlation with clinical indices in patients with hepatitis B virus (HBV) infection. Methods A total of 15 patients with acute hepatitis B (AHB), 30 patients with chronic hepatitis B (CHB), 29 asymptomatic HBV carriers (ASCs), and 12 controls who attended Tangdu Hospital from January 2017 and December 2018 were enrolled. Peripheral blood samples were collected, and plasma and peripheral blood mononuclear cells (PBMCs) were isolated. ELISA was used to measure the plasma levels of interleukin-18 (IL-18) and interferon-γ (IFNγ), and enzyme-linked immunospot assay was used to measure the level of IFNγ secreted by HBV-specific CD8⁺ T cells; flow cytometry was used to measure the percentages of CD3^-CD19⁺CD56⁺CD16⁺ NKB cells, different NK cell subsets (including CD3^-CD19^-CD56^highCD16^- NK cells, CD3^-CD19^-CD56⁺CD16⁺ NK cells, and CD3^-CD19^-CD56^-CD16⁺ NK cells), and their correlation with viral replication and liver inflammation markers was analyzed. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; non-normally distributed continuous data were expressed as M(P₂₅-P₇₅), and the Kruskal-Wallis H test was used for comparison between multiple groups; the Pearson correlation test was used for correlation analysis. Results There was a significant difference in the percentage of CD3^-CD19⁺CD16⁺CD56⁺ NKB cells between the AHB patients, CHB patients, ASCs, and controls (F = 16.42, P < 0.000 1), and the CHB patients had a significantly lower percentage of NKB cells than the AHB patients, ASCs, and controls (0.79%±0.13% vs 0.94%±0.15%/1.02%±0.12%/1.11%±0.27%, all P < 0.001). There was a significant difference in plasma IL-18 level between the AHB patients, CHB patients, ASCs, and controls (F = 5.733, P = 0.001); the CHB patients had a significantly lower IL-18 level than the AHB patients and the controls (259.30±70.09 pg/mL vs 336.00±103.00 pg/mL and 319.30±64.80 pg/mL, both P < 0.05), and ASCs had a significantly lower IL-18 level (258.60±59.82 pg/mL) than the AHB patients and the controls (both P < 0.01), while there was no significant difference in plasma IL-18 level between the CHB patients and ASCs (P = 0.965). There were no significant differences in the percentage of CD3^-CD19^-CD56^highCD16^- NK cells, CD3^-CD19^-CD56⁺CD16⁺ NK cells, CD3^-CD19^-CD56^-CD16⁺ NK cells, and B cells between the four groups (all P > 0.05). The CHB patients had a significantly lower plasma IFNγ level than the AHB patients, ASCs, and controls (all P < 0.01). The percentage of NKB cells and the level of IL-18 were not significantly correlated with HBV DNA quantification or alanine aminotransferase level (all P > 0.05). In the CHB patients, the percentage of NKB cells was positively correlated with plasma IL-18 level (r = 0.432, P = 0.017) and the level of IFNγ secreted by HBV-specific CD8⁺ T cells (r =0.493, P=0.006). Conclusion NKB cells and IL-18 might be involved in the chronicity of HBV infection and is associated with the natural history of chronic HBV infection.
- Hepatitis B virus,
- Natural Killer T-Cells,
- B-Lymphocytes

FullText(HTML)

References(23)

References

[1]	LIN CL, KAO JH. Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants[J]. Best Pract Res Clin Gastroenterol, 2017, 31(3): 249-255. DOI: 10.1016/j.bpg.2017.04.010.
[2]	WU J, HAN M, LI J, et al. Immunopathogenesis of HBV infection[J]. Adv Exp Med Biol, 2020, 1179: 71-107. DOI: 10.1007/978-981-13-9151-4_4.
[3]	WANG S, XIA P, CHEN Y, et al. Natural killer-like B cells prime innate lymphocytes against microbial infection[J]. Immunity, 2016, 45(1): 131-144. DOI: 10.1016/j.immuni.2016.06.019.
[4]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[5]	DONG J, YANG XF, WANG LX, et al. Modulation of tim-3 expression by antigen-dependent and -independent factors on T cells from patients with chronic hepatitis B virus infection [J]. Front Cell Infect Microbiol, 2017, 7: 98. DOI: 10.3389/fcimb.2017.00098.
[6]	LI L, TANG YX, HE W, et al. Estimated sample content of commonly used clinical trial designs [J]. Systems Med, 2018, 3(9): 191-193. DOI: 10.19368/j.cnki.2096-1782.2018.09.191. 李黎, 唐雨欣, 何伟, 等. 常用临床试验设计的样本含量估计[J]. 系统医学, 2018, 3(9): 191-193. DOI: 10.19368/j.cnki.2096-1782.2018.09.191.
[7]	MANICKAM C, NWANZE C, RAM DR, et al. Progressive lentivirus infection induces natural killer cell receptor-expressing B cells in the gastrointestinal tract[J]. AIDS, 2018, 32(12): 1571-1578. DOI: 10.1097/QAD.0000000000001855.
[8]	ZHANG Y, KUANG W, LI D, et al. Natural killer-like B cells secreting interleukin-18 induces a proinflammatory response in periodontitis[J]. Front Immunol, 2021, 12: 641562. DOI: 10.3389/fimmu.2021.641562.
[9]	KERDILES YM, ALMEIDA FF, THOMPSON T, et al. Natural-killer-like B cells display the phenotypic and functional characteristics of conventional B cells[J]. Immunity, 2017, 47(2): 199-200. DOI: 10.1016/j.immuni.2017.07.026.
[10]	RASCLE P, JACQUELIN B, PETITDEMANGE C, et al. NK-B cell cross talk induces CXCR5 expression on natural killer cells[J]. iScience, 2021, 24(10): 103109. DOI: 10.1016/j.isci.2021.103109.
[11]	LIU S, YANG L, JIA S, et al. Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma[J]. Int Immunopharmacol, 2021, 100: 108161. DOI: 10.1016/j.intimp.2021.108161.
[12]	LU Y, BAO JG, DENG Y, et al. Role of IL-18 gene promoter polymorphisms, serum IL-18 levels, and risk of hepatitis B virus-related liver disease in the Guangxi Zhuang Population: a retrospective case-control study[J]. Asian Pac J Cancer Prev, 2015, 16(14): 6019-6026. DOI: 10.7314/apjcp.2015.16.14.6019.
[13]	CHEN YX, HUANG R, WU C. Influence of pregnancy on the natural history of chronic hepatitis B virus infection[J]. J Clin Hepatol, 2019, 35(7): 1430-1434. DOI: 10.3969/j.issn.1001-5256.2019.07.004. 陈雨欣, 黄睿, 吴超. 妊娠对慢性HBV感染自然史的影响[J]. 临床肝胆病杂志, 2019, 35(7): 1430-1434. DOI: 10.3969/j.issn.1001-5256.2019.07.004.
[14]	LIN CL, KAO JH. Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants [J]. Best Pract Res Clin Gastroenterol, 2017, 31(3): 249-255. DOI: 10.1016/j.bpg.2017.04.010.
[15]	LIU S, YANG L, JIA S, et al. Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma[J]. Int Immunopharmacol, 2021, 100: 108161. DOI: 10.1016/j.intimp.2021.108161.
[16]	PENG MJ, YANG XF, WEI X, et al. Influence of hepatitis B virus infection on intrahepatic natural killer cells and innate lymphoid cell 22[J]. J Clin Hepatol, 2016, 32(10): 1883-1887. DOI: 10.3969/j.issn.1001-5256.2016.10.012. 彭梅娟, 杨晓飞, 魏欣, 等. HBV感染对肝脏自然杀伤细胞和固有淋巴样细胞22的影响[J]. 临床肝胆病杂志, 2016, 32(10): 1883-1887. DOI: 10.3969/j.issn.1001-5256.2016.10.012.
[17]	LIANG HJ, CUI YH, WANG YP, et al. Matrix metallopeoteinase regulates natural killer cells function in methicili-resistant staphylococcus aureus sepsis [J]. Chin J Emerg Med, 2020, 29(6): 835-840. DOI: 10.3760/cma.j.issn.1671-0282.2020.06.019. 梁海军, 崔艳慧, 王燕平, 等. 基质金属蛋白酶对MRSA脓毒症患者NK细胞的调控作用[J]. 中华急诊医学杂志, 2020, 29(6): 835-840. DOI: 10.3760/cma.j.issn.1671-0282.2020.06.019.
[18]	QU XJ, LI MH, CAO WH, et al. Study the change of NK cells in HBV infection [J]. Chin J Exp Clin Virol, 2016, 30(5): 439-443. DOI: 10.3760/cma.j.issn.1003-9279.2016.05.006. 屈晓晶, 李明慧, 曹卫华, 等. NK细胞在HBV感染中的作用研究[J]. 中华实验和临床病毒学杂志, 2016, 30(5): 439-443. DOI: 10.3760/cma.j.issn.1003-9279.2016.05.006.
[19]	CAI HN, XU Y, CHEN XY, et al. Effect of HBV infection on biological activity of NK cells cultured in vitro[J/CD]. Chin J Hepat Surg(Electronic Edition), 2020, 9(3): 274-277. DOI: 10.3877/cma.j.issn.2095-3232.2020.03.016. 蔡惠宁, 许燕, 陈晓燕, 等. HBV感染对体外培养NK细胞生物活性影响的研究[J/CD]. 中华肝脏外科手术学电子杂志, 2020, 9(3): 274-277. DOI: 10.3877/cma.j.issn.2095-3232.2020.03.016.
[20]	LIAN JQ, YANG XF, ZHAO RR, et al. Expression profiles of circulating cytokines, chemokines and immune cells in patients with hepatitis B virus infection[J]. Hepat Mon, 2014, 14(6): e18892. DOI: 10.5812/hepatmon.18892.
[21]	JIANG Y, CHEN Y, CHEN L, et al. Impaired circulating CD56dim NK cells are associated with decompensation of HBV-related cirrhosis[J]. Hum Immunol, 2020, 81(1): 32-40. DOI: 10.1016/j.humimm.2019.11.006.
[22]	CHEN Y, TIAN Z. HBV-Induced Immune Imbalance in the Development of HCC[J]. Front Immunol, 2019, 10: 2048. DOI: 10.3389/fimmu.2019.02048.
[23]	CAI Y, YIN W. The multiple functions of B cells in chronic HBV infection[J]. Front Immunol, 2020, 11: 582292. DOI: 10.3389/fimmu.2020.582292.

Relative Articles

[1]	Zexin HU, Jintao HUANG, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Current status and prospects of transarterial chemoembolization and its combined regimens in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(1): 175-180. doi: 10.12449/JCH240129
[2]	Wencong DAI, Mengya ZANG, Guosheng YUAN, Qi LI, Rong LI, Wenli LI, Shuyu DONG, Jinzhang CHEN. Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors[J]. Journal of Clinical Hepatology, 2023, 39(7): 1592-1599. doi: 10.3969/j.issn.1001-5256.2023.07.013
[3]	Xiufeng LIU, Jue ZHANG, Lin YAO, Chaoxu YANG. Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 992-997. doi: 10.3969/j.issn.1001-5256.2022.05.004
[4]	Sirou LI, Yuanlong ZHOU, Keliang LIU, Zhibo LIANG, Jinghua LI. Conversion therapy for massive hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2022, 38(7): 1612-1615. doi: 10.3969/j.issn.1001-5256.2022.07.028
[5]	Kailing XIE, Feng XU. Mechanism of action of Huaier granules in treatment of hepatocellular carcinoma and advances in its clinical application[J]. Journal of Clinical Hepatology, 2022, 38(3): 676-681. doi: 10.3969/j.issn.1001-5256.2022.03.038
[6]	Mengkui HAN, Jin LI, Xiaohua YANG. Function and regulatory mechanism of T lymphocytes in tumor immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2621-2626. doi: 10.3969/j.issn.1001-5256.2022.11.037
[7]	Zhiyuan HOU, Yuan LIU, Chaoran YANG, Jisen ZHAO, Shujie CHENG. Current research status and prospect of circulating tumor DNA in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2616-2620. doi: 10.3969/j.issn.1001-5256.2022.11.036
[8]	Zhiyuan YU, Shiyu YANG, Jiaqi LI, Yan SUN. Current developmental status of non-surgical treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1205-1207. doi: 10.3969/j.issn.1001-5256.2021.05.048
[9]	Tianle GONG, Ping YUE, Jun YAN, Xun LI. Adjuvant therapies after surgery for hepatocellular carcinoma with microvascular invasion[J]. Journal of Clinical Hepatology, 2021, 37(3): 685-688. doi: 10.3969/j.issn.1001-5256.2021.03.037
[10]	Guoxiang CHEN, Mo ZHOU, Sheng CHEN, Yuan WANG, Yuanlong ZHOU, Jihong YANG. Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(3): 699-703. doi: 10.3969/j.issn.1001-5256.2021.03.040
[11]	Shisi LI, Zhitang GUO, Zhangbin CHEN, Yishan TENG. Research advances in systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(12): 2943-2946. doi: 10.3969/j.issn.1001-5256.2021.12.044
[12]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[13]	Ningning ZHANG, Wei LU. Targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1753-1757. doi: 10.3969/j.issn.1001-5256.2021.08.003
[14]	Wang XiaoYun, Li LinFeng, Guo Quan, Ceng YiLan, Li HaiYang, Du YingRong, Chen Gang, Liang YueDong, Lu YinYing. Development and enlightenment of intelligentized diagnostic and therapeutic mode for hepatobiliary tumors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2360-2364. doi: 10.3969/j.issn.1001-5256.2019.10.051
[15]	Shang ZhiYin, Yang JingMao, Chen LiPing, Liu Min, Cheng Kai, Li YaoHua, Ai YingChun, Cheng JiLin. Changes in gastrointestinal structure and function caused by cirrhotic portal hypertension and related clinical manifestations[J]. Journal of Clinical Hepatology, 2017, 33(2): 354-358. doi: 10.3969/j.issn.1001-5256.2017.02.034
[16]	Xu ZhengGuo, Zhao YongBing, Zheng YuanYu, Liu En, Yang ShiMing. Association between portal vein pressure drop gradient after transjugular intrahepatic portosystemic shunt and clinical prognosis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2016.12.019
[17]	Shi XiaoJu, Lyu GuoYue, Zhang Ping, Du XiaoHong, Wang GuangYi. Postoperative application of multidisciplinary treatment in patients with hepatobiliary and pancreatic malignancies[J]. Journal of Clinical Hepatology, 2015, 31(11): 1886-1888. doi: 10.3969/j.issn.1001-5256.2015.11.028
[18]	Society of Liver Cancer, Guangdong Provincial Anti-cancer Association. Strategy and method of multi-disciplinary comprehensive treatment of liver cancer-consensus of experts in Guangdong, China (2)[J]. Journal of Clinical Hepatology, 2014, 30(11): 1116-1119. doi: 10.3969/j.issn.1001-5256.2014.11.005
[19]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[20]	Wang JiYao. Importance of detecting portal hypertension in liver cirrhosis patients: theory, research tools, and clinical applications[J]. Journal of Clinical Hepatology, 2012, 28(9): 642-643.

Supplements(0)

Cited By

Cited by

Periodical cited type(20)

1.	秦鹏，李树森，刘皓，吴广迎. 胃冠状静脉栓塞术在门脉高压性上消化道出血经颈静脉肝内门腔静脉分流术患者中的临床疗效. 血管与腔内血管外科杂志. 2022(09): 1130-1134 .
2.	高绍，王宏亮，聂春晖，张岳林，周坦洋，余子牛，杨月，孙军辉. 对比TIPS联合胃冠状静脉栓塞术与单独TIPS治疗肝硬化门静脉高压伴上消化道出血的中远期疗效：Meta分析. 中国介入影像与治疗学. 2022(11): 673-677 .
3.	张大维，吴东辉，孙兴安. TIPS对肝硬化并发上消化道出血患者近期肝肾功能和远期疗效的影响. 当代医学. 2021(35): 129-130 .
4.	林纲毅，马洺远，蔡宗洋. 超声引导下门静脉穿刺导引经颈静脉肝内门体分流术联合曲张静脉栓塞治疗食管胃底静脉曲张破裂出血的临床效果. 中国当代医药. 2020(07): 113-116 .
5.	王宁，林芳明，吕明. TIPS联合GCVE用于门静脉高压并发上消化道大出血的应用价值. 肝脏. 2020(09): 952-954 .
6.	韩志强. 肝硬化上消化道出血37例外科临床治疗效果观察. 世界最新医学信息文摘. 2019(05): 95+102 .
7.	张明礼. PTVE联合PSE治疗肝硬化门脉高压并上消化道出血的观察. 实用中西医结合临床. 2019(05): 24-26 .
8.	孙允涛. 肝硬化门静脉高压并发上消化道出血的相关危险因素分析. 中国民康医学. 2019(10): 81-83 .
9.	孙巧玉，赖雪珍，河源媛. 门脉高压合并上消化道出血采用PTVE联合PSE手术的效果分析. 现代消化及介入诊疗. 2019(08): 837-841+846 .
10.	杨荣焕. TIPS和PTVE介入方法治疗肝硬化门静脉高压引起的上消化道出血的优劣差异. 黑龙江医学. 2019(09): 1012-1013+1016 .
11.	武和平. 不同介入途径胃冠状静脉栓塞术治疗肝硬化门静脉高压出血的临床疗效观察. 现代消化及介入诊疗. 2018(02): 208-210 .
12.	李广忠. 分析肝硬化门脉高压症下食管静脉曲张破裂出血的危险因素. 智慧健康. 2018(07): 91-92+126 .
13.	李贤圣，董勤勇，张乐，夏侨，贺军. 经颈静脉门静脉分流术介入治疗门静脉高压引起上消化道出血的疗效分析. 浙江创伤外科. 2018(02): 272-273 .
14.	赵晓飞，林栋栋，李宁，臧运金，郭庆良，武聚山. 门静脉高压患者脾切断流术后曲张静脉再出血的危险因素分析. 临床肝胆病杂志. 2018(10): 2182-2185 . 本站查看
15.	吴笋. 经颈静脉肝内门体静脉分流术加胃冠状静脉栓塞术治疗门脉高压症初探. 现代医用影像学. 2018(05): 1522-1523+1528 .
16.	田广俊，池晓玲，常钢，孟凡喆，曹敏玲，黎英贤，徐浩祥，梁宏才，赵朋涛，吴晓菊，萧焕明. 中药灌肠防治TIPS治疗肝硬化门静脉高压伴上消化道出血术后肝性脑病临床观察. 新中医. 2018(12): 87-91 .
17.	樊春燕，叶晓丽，戴晓婷，吴宇清. 肝硬化门静脉高压并发上消化道出血的相关性分析研究. 血管与腔内血管外科杂志. 2018(05): 381-385 .
18.	彭虹. 肝硬化门静脉高压并发上消化道出血的相关危险因素分析. 中国继续医学教育. 2017(31): 58-59 .
19.	张志勇. 不同手术方案治疗肝硬化门脉高压症的临床对比. 临床医药文献电子杂志. 2017(46): 8924-8925 .
20.	向平，张川，张亮科，唐瑞强，叶继彬. 1例上消化道出血病人护理体会. 世界最新医学信息文摘. 2016(14): 247 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (800) PDF downloads(69)

Changes and clinical significance of natural killer-like B cells, natural killer cells, and B cells in peripheral blood of patients with hepatitis B virus infection

DOI: 10.3969/j.issn.1001-5256.2022.07.008